Consortium will use QSP to predict the immunogenicity of biologics and its impact on pharmacokinetics, efficacy and safety in diverse patient populations
PRINCETON, NJ – Jan. 25, 2017 – Certara®, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced that it is launching a Quantitative Systems Pharmacology (QSP) Immunogenicity Consortium. 大きな成果を挙げてきた当社の Simcyp® コンソーシアムをモデルとする QSP 免疫原性コンソーシアムは、業界初の試みとなっています。このコンソーシアムでは、医薬品業界を牽引する製薬企業が競争前の基礎研究段階の環境に集まり、生物製剤の免疫原性や、多様な患者集団における薬物動態、有効性および安全性に与える影響を予測する Immunogenicity Simulator を共同開発することを目的として設立されました。
Immunogenicity is defined by the US Food and Drug Administration (FDA) as the propensity of the therapeutic protein product to generate immune responses to itself and to related proteins or to induce immunologically-related adverse clinical events. In a recent US FDA review of 121 approved biological products, 89 percent of them had immunogenicity reported and in 49 percent of cases it impacted efficacy. Immunogenicity is especially concerning for vulnerable populations with compromised immune systems, oftentimes the exact cohort receiving the biologic treatment.
“Clients rely on Simcyp to research and provide cutting-edge solutions to understand and manage complex physiological drug reactions. Just as sponsors now use mechanistic physiologically-based pharmacokinetic (PBPK) modeling and simulation via the Simcyp Simulator to manage drug-drug interactions (DDIs) and dosing for special populations, they will be able to use these new QSP models to manage immune responses,” said Simcyp President and Managing Director Steve Toon, PhD. “Our models and software tools will enable sponsors to manage immunogenicity by adjusting the biologic dose, route of administration, patient population and/or co-medications. It may also be possible to moderate the immune system’s tolerance of the drug.”
“As immunogenicity to treatment is such a complex process, we need both QSP and mechanistic models of the humoral and cellular responses involved to fully understand it,” said Professor Piet van der Graaf, PharmD, PhD, vice president and head of Certara QSP. “Current immunogenicity modeling uses machine learning to predict immunogenicity directly from the biologic drug’s genetic sequence. This is insufficient because it doesn’t account for the full complexity and dynamics of potential physiological responses or the differences between patient populations.”
“We will use a variety of structural, in vitro and in vivo input parameters for our dynamic models, which will be implemented in a robust IT platform coupled to a virtual patient simulator that can be used to make development and regulatory decisions,” added Professor van der Graaf.
Most of the top-40 pharmaceutical companies (including all of the top 10), along with the major regulatory bodies are members of the Simcyp Consortium, which uses Certara’s Simcyp Simulator PBPK modeling and simulation platform to select the most appropriate drug doses, design optimal clinical trials, evaluate new drug formulations, and predict DDIs and PK outcomes in clinical populations. Simcyp Simulatorに搭載されるモデルは、医薬品添付文書の記載内容に関わる知見を獲得する目的で広く用いられています。
Mechanistic modeling of PK is now an expected component in regulatory submissions and it is anticipated that QSP modeling will become a requirement as well.
Certara’s Immunogenicity Simulator will help inform the clinical development for biologicals by allowing sponsors to explore optimal dosing routes and regimens, and answer ‘what-if’ questions in virtual patient populations.
Biologics currently comprise one third of all new drug approvals by the US FDA. By 2019, they are predicted to generate $445 billion of sales revenue.
Certara（サターラ）について
Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies.
お問合せ先
Ellen Leinfuss, 609-216-9586
Chief Marketing Officer
報道機関の皆様：
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com
